Discover comprehensive details about Mycophenolate Mofetil, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

TORONTO, June 4 /PRNewswire/ -- The 12-month results from a multicenter trial monitoring CellCept(R) (mycophenolate mofetil) in combination with calcineurin inhibitors (CNIs) in renal transplantation ...

Embryo-fetal toxicity; rule out pregnancy with serum or urine pregnancy test immediately before starting therapy, then another test 8–10 days later. Repeat pregnancy tests during routine follow-up ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving mycophenolate mofetil combination therapies saw increased seroconversion after a third dose ...

♦Contraindicated to pregnant women and patients with known hypersensitivity. It should not be co-administered with Proton Pump Inhibitors (PPIs).

Renal and Urology News, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve ...

Seattle, May 25 – Monitoring the level of CellCept® (mycophenolate mofetil) in a patient's blood in the months following an organ transplant may enable physicians to identify the precise amount of ...

June 9, 2006 — The U.S. Food and Drug Administration (FDA) has approved orphan drug status for mycophenolate mofetil in the treatment of pemphigus vulgaris; second-generation antisense drug for the ...

CellCept (mycophenolate mofetil) is a prescription drug used to prevent organ rejection after certain organ transplants. CellCept’s cost may depend on factors such as your dosage, whether you have ...

The addition of mycophenolate mofetil (MMF) to a glucocorticoid as a first-line treatment for immune thrombocytopenia (ITP) resulted in greater responses and a reduced risk of relapse or refractory ...